BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 6086533)

  • 1. Complement components, complement activation, and acute phase response in systemic lupus erythematosus.
    Sturfelt G; Sjöholm AG
    Int Arch Allergy Appl Immunol; 1984; 75(1):75-83. PubMed ID: 6086533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement components, C1 activation and disease activity in SLE.
    Sturfelt G; Sjöholm AG; Svensson B
    Int Arch Allergy Appl Immunol; 1983; 70(1):12-8. PubMed ID: 6293980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential studies of complement activation in systemic lupus erythematosus.
    Sturfelt G; Johnson U; Sjöholm AG
    Scand J Rheumatol; 1985; 14(2):184-96. PubMed ID: 4001891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus.
    Jonsson H; Sturfelt G; Mårtensson U; Truedsson L; Sjöholm AG
    Clin Exp Rheumatol; 1995; 13(5):573-80. PubMed ID: 8575134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of (C1INH)2 C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation.
    Waldo FB; West CD
    Clin Immunol Immunopathol; 1987 Feb; 42(2):239-49. PubMed ID: 3026704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1 subcomponent complexes and C2 cleavage in active systemic lupus erythematosus.
    Jonsson H; Sjöholm AG; Mårtensson U; Laurell AB; Sturfelt G
    Complement Inflamm; 1991; 8(1):1-12. PubMed ID: 2049932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating immune complexes and C1 activation in patients with rapidly progressive glomerulonephritis, before and after treatment with immunosuppression and plasma exchange.
    Sjöholm AG; Brun C; Larsen S; Thysell H
    Int Arch Allergy Appl Immunol; 1983; 72(1):9-15. PubMed ID: 6874103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocomplementemia with low C1s-C1 inhibitor complex in systemic lupus erythematosus.
    Lockshin MD; Qamar T; Redecha P; Harpel PC
    Arthritis Rheum; 1986 Dec; 29(12):1467-72. PubMed ID: 3492208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).
    Lloyd W; Schur PH
    Medicine (Baltimore); 1981 May; 60(3):208-17. PubMed ID: 7231154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement components and activation in primary biliary cirrhosis.
    Lindgren S; Laurell AB; Eriksson S
    Hepatology; 1984; 4(1):9-14. PubMed ID: 6420306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential characteristics of immune-bound antibodies in diffuse proliferative and membranous forms of lupus glomerulonephritis.
    Roberts JL; Wyatt RJ; Schwartz MM; Lewis EJ
    Clin Immunol Immunopathol; 1983 Nov; 29(2):223-41. PubMed ID: 6605223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Components of the classical complement pathway in systemic lupus erythematosus].
    Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M
    Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
    Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
    Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
    [No Abstract]   [Full Text] [Related]  

  • 17. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical hypocomplementemic vasculitis syndrome in a child.
    Waldo FB; Leist PA; Strife CF; Forristal J; West CD
    J Pediatr; 1985 May; 106(5):745-50. PubMed ID: 2987470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited complement deficiency states and SLE.
    Rynes RI
    Clin Rheum Dis; 1982 Apr; 8(1):29-47. PubMed ID: 6288318
    [No Abstract]   [Full Text] [Related]  

  • 20. C-reactive protein and complement components but not other acute-phase reactants discriminate between clinical subsets and organ damage in systemic lupus erythematosus.
    Amezcua-Guerra LM; Springall R; Arrieta-Alvarado AA; Rodríguez V; Rivera-Martinez E; Castillo-Martinez D; Bojalil R
    Clin Lab; 2011; 57(7-8):607-13. PubMed ID: 21888025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.